@article{ref1,
title="Serum soluble TWEAK levels in severe traumatic brain injury and its prognostic significance",
journal="Clinica chimica acta: international journal of clinical chemistry",
year="2019",
author="Tang, Bei and Zhong, Ze and Qiu, Zheng and Wu, Hui-Ping and Hu, Jia-Yuan and Ma, Jian-Ping and Wu, Jin-Ping",
volume="495",
number="",
pages="227-232",
abstract="BACKGROUND: Severe traumatic brain injury (sTBI) is characterized by a high mortality. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) participates in inflammation. We determined serum soluble TWEAK (sTWEAK) levels with respect to its prognostic ability. <br><br>METHODS: This was a single-center prospective, observational study that was performed from December 2014 to December 2017. A total of 114 sTBI patients who met the inclusion criteria and 114 randomly selected healthy controls were included in the study. Serum sTWEAK levels were gauged. Patients were followed-up until death or completion of 6 months. Poor outcome was referred to as Glasgow outcome scale score of 1-3. <br><br>RESULTS: In comparison with controls, patients displayed predominantly higher serum sTWEAK levels. Serum sTWEAK levels were strongly correlated with Glasgow coma scale scores and serum C-reactive protein levels. 32 patients (28.1%) died and 60 patients (52.6%) suffered from a poor outcome. Receiver operating characteristic curve analysis clearly showed that serum sTWEAK levels had substantially high predictive performance for 6-month mortality and poor outcome. Serum sTWEAK emerged as an independent predictor for 6-month mortality, overall survival and poor outcome. <br><br>CONCLUSIONS: Raised serum sTWEAK levels are closely related to increasing inflammatory response, elevated trauma severity and worse clinical outcome after sTBI.<br><br>Copyright © 2019. Published by Elsevier B.V.<p /> <p>Language: en</p>",
language="en",
issn="0009-8981",
doi="10.1016/j.cca.2019.04.070",
url="http://dx.doi.org/10.1016/j.cca.2019.04.070"
}